This company has been acquired
Radius Health (RDUS) Stock Overview
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
RDUS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Radius Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.10 |
| 52 Week High | US$23.00 |
| 52 Week Low | US$4.97 |
| Beta | 0.52 |
| 1 Month Change | -0.39% |
| 3 Month Change | 78.76% |
| 1 Year Change | -27.08% |
| 3 Year Change | -55.21% |
| 5 Year Change | -71.49% |
| Change since IPO | 26.09% |
Recent News & Updates
Radius Recycling's Surge Justifies A Reevaluation
Summary Radius Recycling, Inc. shares surged after agreeing to a $30 per share buyout by Toyota Tsusho, offering a 115% premium over the closing price. Despite operational challenges and declining revenues, the buyout provides a significant 77.8% upside since my “buy” rating in June last year. Toyota Tsusho's acquisition reflects their strategic interest in metals recycling, but they assume all risks amid potential market recovery and volatility. Given the substantial premium and limited future upside, I recommend downgrading RDUS stock to a “hold” to align with broader market performance expectations. Read the full article on Seeking AlphaRadius Recycling Will Benefit From Steel Tariffs
Summary Radius Recycling's profitability is poised to improve due to rising domestic steel prices driven by tariffs, which will increase scrap steel prices and expand margins. Despite historical underperformance, the company's margins will benefit from higher scrap prices without significant cost increases, making it a speculative buy. Monitoring scrap steel prices before Radius's next earnings report could reveal an undervalued stock if the market hasn't yet recognized this linkage. Investing in Radius should be modest, as its viability heavily relies on the continuation of steel tariffs boosting scrap prices. Read the full article on Seeking AlphaRadius Recycling Stays In The Scrap Pile
Summary Radius Recycling experienced a significant decline in share price, hitting a 52-week low of $12.72. The company is implementing strategic changes to boost profits, including upgrades to non-ferrous scraping capabilities and cost reduction initiatives. Economic indicators such as durable goods orders, average vehicle age, and Chinese steel export production will impact Radius Recycling's business in the near future. Read the full article on Seeking AlphaRadius Recycling: An Attractive, But Volatile, Play On A Cleaner Future
Summary Radius Recycling, Inc. is a large recycler of ferrous and nonferrous metal, with operations in metals recycling, auto parts stores, and steel manufacturing. The company's financial performance has been volatile due to fluctuating steel prices, but its stock is trading at low multiples. Despite short-term challenges, the long-term potential of the recycling industry makes Radius Recycling a cheap business worth considering. Read the full article on Seeking AlphaRadius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
The U.S. Food and Drug Administration (FDA) granted priority review to Menarini's application seeking approval of elacestrant to treat patients with ER+/HER2- advanced or metastatic breast cancer. The FDA accepted the Italian pharmaceutical and diagnostic company's new drug application (NDA) and is expected to make a decision by Feb. 17, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 3 trial called EMERALD, which was conducted by Radius Health (NASDAQ:RDUS). Menarini had obtained global licensing rights for elacestrant from Radius in July 2020. Menarini noted that it had filed for approval of the drug in the EU in July 2022. Elacestrant had received the FDA's fast track designation in 2018. RDUS +5.56% to $10.64 premarket Aug. 11Recent updates
Shareholder Returns
| RDUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.1% | -2.4% | 0.7% |
| 1Y | -27.1% | 35.9% | 20.6% |
Return vs Industry: RDUS underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: RDUS underperformed the US Market which returned -11.6% over the past year.
Price Volatility
| RDUS volatility | |
|---|---|
| RDUS Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RDUS's share price has been volatile over the past 3 months.
Volatility Over Time: RDUS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 293 | G. Martin | radiuspharm.com |
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company’s commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome.
Radius Health, Inc. Fundamentals Summary
| RDUS fundamental statistics | |
|---|---|
| Market cap | US$480.77m |
| Earnings (TTM) | -US$68.63m |
| Revenue (TTM) | US$223.36m |
Is RDUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDUS income statement (TTM) | |
|---|---|
| Revenue | US$223.36m |
| Cost of Revenue | US$19.47m |
| Gross Profit | US$203.89m |
| Other Expenses | US$272.52m |
| Earnings | -US$68.63m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 91.28% |
| Net Profit Margin | -30.72% |
| Debt/Equity Ratio | -124.2% |
How did RDUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/11 17:27 |
| End of Day Share Price | 2022/08/11 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Radius Health, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| John Newman | Canaccord Genuity |
| Mara Goldstein | Cantor Fitzgerald & Co. |